Kiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 1-Year High at $16.67

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Rating) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $16.67 and last traded at $16.58, with a volume of 2430 shares traded. The stock had previously closed at $15.86.

Wall Street Analyst Weigh In

Separately, TheStreet raised Kiniksa Pharmaceuticals from a “d” rating to a “c+” rating in a report on Friday, November 4th.

Kiniksa Pharmaceuticals Trading Down 1.6 %

The stock has a fifty day moving average of $13.34 and a two-hundred day moving average of $11.31. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 7.80 and a beta of -0.27.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of KNSA. Lazard Asset Management LLC increased its holdings in Kiniksa Pharmaceuticals by 52.2% during the 1st quarter. Lazard Asset Management LLC now owns 5,720 shares of the company’s stock valued at $56,000 after purchasing an additional 1,961 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Kiniksa Pharmaceuticals by 19.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,549 shares of the company’s stock valued at $83,000 after buying an additional 1,385 shares during the period. Legal & General Group Plc increased its stake in shares of Kiniksa Pharmaceuticals by 25.3% in the 2nd quarter. Legal & General Group Plc now owns 10,714 shares of the company’s stock valued at $103,000 after buying an additional 2,162 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at $130,000. Finally, Thrivent Financial for Lutherans acquired a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at $152,000. 43.22% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

(Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

See Also

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.